Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic avenue for managing metabolic disorders. These naturally occurring hormones are secreted by the gut in response to nutrient intake, stimulating insulin production and suppressing glucagon output. GLP-1 peptides exhibit promising therapeutic efficacy in treating type